A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524).

@article{Michaelson2017AP1,
  title={A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524).},
  author={Marc Dror Michaelson and Chen Hu and H. T. L. Pham and Douglas M. Dahl and Chin Lee-Wu and Gregory P. Swanson and Jacqueline Vuky and Robert J Lee and Luis Souhami and Brian Chang and Asha George and Howard Mark Sandler and William U. Shipley},
  journal={International journal of radiation oncology, biology, physics},
  year={2017},
  volume={97 5},
  pages={995-1001}
}
PURPOSE Bladder preservation therapy is an effective treatment for muscle-invasive urothelial carcinoma (UC). In this study we treated noncystectomy candidates with daily radiation and weekly paclitaxel for 7 weeks. Patients whose tumors showed her2/neu overexpression were additionally treated with weekly trastuzumab. METHODS AND MATERIALS Sixty-eight… CONTINUE READING